NSE: GLAND | BSE: 543245

Strong Performer, Getting Expensive

Download real time

2507.00 -36.70 (-1.44%)

New 52W High today

524.3K NSE+BSE Volume

NSE 30 Jul, 2026 10:49 AM (IST)

41,355.4

Market Cap

High in industry

Beta 1Year

Very Low volatility

US FDA Approval

Gland Pharma gets US FDA approval for an anaesthesia reversal drug, with US sales of around $1.6 bn See details

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Search Inside the pdf :

Gland Pharma Ltd.

22 May 2026

2507.00

-1.44%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

About the stock: Gland Pharma is one of the largest generic injectable-focused Along with its partners, Gland owns 1,748 products registrations globally of which ~490 in US, Europe, Canada, Australia, and New Zealand, ~73 in...

Gland Pharma has gained 39.27% in the last 6 Months

Gland Pharma Ltd.

29 Jan 2026, 12:00AM

2507.00

-1.44%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Recommendation

Axis Direct

We maintain our BUY rating on the stock.

Gland Pharma Ltd. is trading above all available SMAs

Gland Pharma Ltd.

29 Jan 2026, 12:00AM

2507.00

-1.44%

Gland Pharma

Buy: Gland Pharma Ltd.

Target

ICICI Direct

Gland Pharma has gained 44.16% in the last 3 Months

Gland Pharma Ltd.

28 Jan 2026

2507.00

-1.44%

Cenexi break-even/US uptrend drives earnings beat

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered better-than-expected 3QFY26 financial performance with a 6%/14%/19% beat on revenue/EBITDA/PAT.

Gland Pharma has gained 44.16% in the last 3 Months

Gland Pharma Ltd.

04 Nov 2025

2507.00

-1.44%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We revise our rating from HOLD to BUY

Gland Pharma Ltd. has an average target of 2288.33 from 3 brokers.

Gland Pharma Ltd.

04 Nov 2025

2507.00

-1.44%

Gland Pharma

Buy: Gland Pharma Ltd.

ICICI Direct

Number of FII/FPI investors increased from 230 to 286 in Jun 2026 qtr.

Gland Pharma Ltd.

04 Nov 2025

2507.00

-1.44%

In-line revenue; margin miss transient

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lowerthan-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.